专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08883164B2 Targeted identification of immunogenic peptides 有权
标题翻译：免疫原性肽的靶向鉴定
公开(公告)号：US08883164B2
公开(公告)日：2014-11-11
申请号：US13336068
申请日：2011-12-23
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： G01N33/6803 , A61K39/0011 , A61K39/39558 , C07K16/32 , C40B30/02 , G01N33/5011 , G01N33/564 , G01N33/574 , G01N33/577 , G01N33/6845 , G01N2500/00 , G01N2500/04 , A61K2300/00
摘要： This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
摘要翻译：本发明一般涉及鉴定涉及抗体与任何蛋白质结合的肽序列，用于疫苗治疗的合成。这种新方法允许更易于管理的疫苗肽发现，并且仅在抗体存在下才能特异性地产生来自感染性生物体的自身肿瘤相关蛋白和/或特异性和/或增强表达的独特的免疫原性肽。

2. 发明申请

US20080260745A1 TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES 有权
标题翻译：目标鉴定免疫原性肽
公开(公告)号：US20080260745A1
公开(公告)日：2008-10-23
申请号：US12045402
申请日：2008-03-10
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
IPC分类号： A61K39/395 , G01N33/53 , A61P35/00 , C07K14/47 , C07K16/18
CPC分类号： G01N33/6803 , A61K39/0011 , A61K39/39558 , C07K16/32 , C40B30/02 , G01N33/5011 , G01N33/564 , G01N33/574 , G01N33/577 , G01N33/6845 , G01N2500/00 , G01N2500/04 , A61K2300/00
摘要： This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
摘要翻译：本发明一般涉及鉴定涉及抗体与任何蛋白质结合的肽序列，用于疫苗治疗的合成。这种新方法允许更易于管理的疫苗肽发现，并且仅在抗体存在下才能特异性地产生来自感染性生物体的自身肿瘤相关蛋白和/或特异性和/或增强表达的独特的免疫原性肽。

3. 发明授权

US08945573B2 Targeted identification of immunogenic peptides 有权
公开(公告)号：US08945573B2
公开(公告)日：2015-02-03
申请号：US12045402
申请日：2008-03-10
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
IPC分类号： A61K39/00 , A61K39/395
CPC分类号： G01N33/6803 , A61K39/0011 , A61K39/39558 , C07K16/32 , C40B30/02 , G01N33/5011 , G01N33/564 , G01N33/574 , G01N33/577 , G01N33/6845 , G01N2500/00 , G01N2500/04 , A61K2300/00
摘要： This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.

4. 发明申请

US20120107311A1 TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES 有权
标题翻译：目标鉴定免疫原性肽
公开(公告)号：US20120107311A1
公开(公告)日：2012-05-03
申请号：US13336068
申请日：2011-12-23
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： G01N33/6803 , A61K39/0011 , A61K39/39558 , C07K16/32 , C40B30/02 , G01N33/5011 , G01N33/564 , G01N33/574 , G01N33/577 , G01N33/6845 , G01N2500/00 , G01N2500/04 , A61K2300/00
摘要： This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
摘要翻译：本发明一般涉及鉴定涉及抗体与任何蛋白质结合的肽序列，用于疫苗治疗的合成。这种新方法允许更易于管理的疫苗肽发现，并且仅在抗体存在下才能特异性地产生来自感染性生物体的自身肿瘤相关蛋白和/或特异性和/或增强表达的独特的免疫原性肽。

5. 发明授权

US08133691B2 Stable quantitation and detection of immune response levels with non-zero background peptides 失效
标题翻译：用非零背景肽稳定定量和检测免疫应答水平
公开(公告)号：US08133691B2
公开(公告)日：2012-03-13
申请号：US11994794
申请日：2006-07-05
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Michael Flora
IPC分类号： G01N33/00 , G01N33/543 , A61K38/04
CPC分类号： G01N33/505 , G01N33/54346 , Y10T436/25375
摘要： The invention relates to a kit comprising MHC Class I and Class II HLA-coated beads containing specific antigenic peptides for binding to antigen-specific T cells and the appropriate negative control peptides. Also provided are methods for making the coated beads and methods for use. The application of these beads go to the stimulation of peripheral blood cell populations and in vitro-stimulated culture for the elicitation of functional activities such as cell activation and signaling, cytokine secretion, proliferation and cytotoxicity activity.
摘要翻译：本发明涉及包含MHC I类和II类HLA包被的珠的试剂盒，其包含用于结合抗原特异性T细胞的特异性抗原肽和适当的阴性对照肽。还提供了制备涂覆珠粒的方法和使用方法。这些珠粒的应用去激发外周血细胞群体和体外刺激的培养物以引发功能活性如细胞活化和信号传导，细胞因子分泌，增殖和细胞毒性活性。

6. 发明申请

US20080300203A1 Stable Quantitation and Detection of Immune Response Levels with Non-Zero Background Peptides 失效
标题翻译：用非零背景肽稳定定量和检测免疫反应水平
公开(公告)号：US20080300203A1
公开(公告)日：2008-12-04
申请号：US11994794
申请日：2006-07-05
申请人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Flora Michael
发明人： Sathibalan Ponniah , George E. Peoples , Catherine E. Storrer , Flora Michael
IPC分类号： A61K31/70 , C07K7/00 , C07K14/00 , C07H21/04 , A61P37/00 , G01N33/53 , C07K16/18 , C12Q1/68
CPC分类号： G01N33/505 , G01N33/54346 , Y10T436/25375
摘要： The invention relates to a kit comprising MHC Class I and Class II HLA-coated beads containing specific antigenic peptides for binding to antigen-specific T cells and the appropriate negative control peptides. Also provided are methods for making the coated beads and methods for use. The application of these beads go to the stimulation of peripheral blood cell populations and in vitro-stimulated culture for the elicitation of functional activities such as cell activation and signaling, cytokine secretion, proliferation and cytotoxicity activity.
摘要翻译：本发明涉及包含MHC I类和II类HLA包被的珠的试剂盒，其包含用于结合抗原特异性T细胞的特异性抗原肽和适当的阴性对照肽。还提供了制备涂覆珠粒的方法和使用方法。这些珠粒的应用去激发外周血细胞群体和体外刺激的培养物以引发功能活性如细胞活化和信号传导，细胞因子分泌，增殖和细胞毒性活性。

7. 发明申请

US20100255019A1 Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE 审中-公开
标题翻译： Ii-KEY / HER-2 / NEU混合型疫苗
公开(公告)号：US20100255019A1
公开(公告)日：2010-10-07
申请号：US12643509
申请日：2009-12-21
申请人： Robert Humphreys , Minzhen Xu , George E. Peoples , Sathibalan Ponniah
发明人： Robert Humphreys , Minzhen Xu , George E. Peoples , Sathibalan Ponniah
IPC分类号： A61K39/00 , A61P35/00
CPC分类号： A61K39/0011 , A61K2039/55516 , A61K2039/55522
摘要： Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO.: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide.
摘要翻译：提供用于治疗人类癌症的方法和组合物，该癌症的特征在于Her-2 / neu的表达。所述方法涉及用Ii-Key / MHC II类杂交构建体接种患者，从而刺激对天然Her-2 / neu蛋白的免疫应答。构建体可以是Ii-Key杂交肽或编码Ii-Key杂交肽的核酸的形式。描述了其中所治疗的癌症是乳腺癌的方法。还要求保护的是包含具有和不具有佐剂的Ii-Key / MHC II类杂交构建体的药物组合物。佐剂可以包括GM-CSF。 Ii-Key杂交构建体包括用于疫苗的蛋白质或其部分的Ii-Key蛋白的LRMK [SEQ ID NO.:2]残基和MHC II类表位或编码相同杂交肽的DNA。

8. 发明授权

US08815256B2 Induction of tumor immunity by variants of folate binding protein 有权
标题翻译：通过叶酸结合蛋白的变体诱导肿瘤免疫
公开(公告)号：US08815256B2
公开(公告)日：2014-08-26
申请号：US13556876
申请日：2012-07-24
申请人： Constantin G. Ioannides , George E. Peoples , Kathleen G. Peoples
发明人： Constantin G. Ioannides , George E. Peoples
IPC分类号： A61K39/00 , C07K14/47
CPC分类号： C07K7/06 , A61K38/00 , A61K39/00 , A61K39/0011 , A61K39/17 , A61K2039/54 , A61K2039/545 , C07K14/47
摘要： The present invention is directed to variants of antigens comprising folate binding protein epitopes as a composition associated with providing immunity against a tumor in an individual. The variant is effective in inducing cytotoxic T-lymphocytes but preferably not to the extent that they become sensitive to silencing by elimination, such as by apoptosis, or by anergy, as in unresponsiveness.
摘要翻译：本发明涉及包含叶酸结合蛋白表位作为与个体中提供针对肿瘤的免疫相关的组合物的抗原变体。该变体在诱导细胞毒性T淋巴细胞方面是有效的，但是优选地不是通过消除如通过凋亡或无反应性的消除而变得敏感的程度，如在无应答中。

9. 发明授权

US08222214B2 Vaccine for the prevention of breast cancer relapse 有权
标题翻译：疫苗用于预防乳腺癌复发
公开(公告)号：US08222214B2
公开(公告)日：2012-07-17
申请号：US12602214
申请日：2008-04-11
申请人： George E. Peoples , Ponniah Sathibalan
发明人： George E. Peoples , Ponniah Sathibalan
IPC分类号： A61K38/00
CPC分类号： A61K39/0011 , A61K38/179 , A61K38/193 , A61K39/00 , A61K39/39 , A61K2039/545 , A61K2039/55522 , C07K14/71
摘要： The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective or therapeutic immunity against breast cancer in a patient in clinical remission. The methods comprise administering to the patient an effective amount of a vaccine composition comprising a pharmaceutically acceptable carrier, an adjuvant such as recombinant human GM-CSF, and the E75 peptide at an optimized dose and schedule. The methods further comprise administering an annual or semi-annual booster vaccine dose due to declining E75-specific T cell immunity. The invention also features vaccine compositions for use in the methods.
摘要翻译：本发明的特征在于诱导和维持对HER2 / neu癌基因E75的肽的保护性细胞毒性T淋巴细胞应答的方法，其具有在临床缓解患者中诱导和维持对乳腺癌的保护性或治疗性免疫的作用。所述方法包括以优化的剂量和时间表向患者施用有效量的包含药学上可接受的载体，佐剂如重组人GM-CSF和E75肽的疫苗组合物。该方法还包括由于E75特异性T细胞免疫力下降而施用一年或半年一次的加强疫苗剂量。本发明还特征在于用于该方法的疫苗组合物。

10. 发明授权

US08802618B2 Controlled modulation of amino acid side chain length of peptide antigens 有权
标题翻译：肽抗原氨基酸侧链长度的控制调节
公开(公告)号：US08802618B2
公开(公告)日：2014-08-12
申请号：US10507009
申请日：2003-03-06
申请人： Constantin G. Ioannides , Martin L. Campbell , Catherine A. O'Brian , George E. Peoples
发明人： Constantin G. Ioannides , Martin L. Campbell , Catherine A. O'Brian , George E. Peoples
IPC分类号： A61K31/00 , A61K35/00 , A61K38/08 , A61K39/00
CPC分类号： C07K7/06 , C07K14/4705
摘要： The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension or shortening of the side chain with CH3/CH2 groups, for example, made by computer assisted modeling of the tumor antigen (peptide) bound in the MHC-I-groove, immunogenicity can be improved with minimal modification of adjacent tertiary structure, thereby avoiding cross-reactivity. Provided by the invention are methods of creating such antigens, as well as methods for therapeutic or prophylactic treatment of various conditions comprising administration of the antigens.
摘要翻译：本发明提供了一种产生肽抗原的方法，其包含具有至少第一修饰的表位，所述第一修饰包含缩短或延长的氨基酸侧链。通过用CH 3 / CH 2基团延伸或缩短侧链，例如通过在MHC-1-沟槽中结合的肿瘤抗原（肽）的计算机辅助建模制备，可以通过相邻三级结构的最小修饰来改善免疫原性，从而避免交叉反应。通过本发明提供了产生这种抗原的方法，以及用于治疗或预防性治疗包括施用抗原的各种病症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式